Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

X Du, B Yang, Q An, YG Assaraf, X Cao, J Xia - The Innovation, 2021 - cell.com
The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight

S Singh, S Sadhukhan, A Sonawane - Biochimica et Biophysica Acta (BBA) …, 2023 - Elsevier
Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

[HTML][HTML] Overall treatment strategy for patients with metastatic NSCLC with activating EGFR mutations

H Hayashi, E Nadal, JE Gray, A Ardizzoni, N Caria… - Clinical lung cancer, 2022 - Elsevier
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are
standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung …

Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents

H Prabhavathi, KR Dasegowda… - Journal of …, 2022 - Taylor & Francis
Breast cancer is the most prevalent cancer in women worldwide. To treat human breast
cancer by inhibiting EGFR and HER2 targets is an important therapeutic option …

New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies

SS Hawas, SM El-Sayed, PA Elzahhar… - Bioorganic Chemistry, 2023 - Elsevier
New series of substituted 2-alkoxycyanopyridine derivatives were synthesized and
evaluated for their in vitro and in vivo anticancer activities. Comparing the evaluated …

Antibacterial efficacy of N-(4-methylpyridin-2-yl) thiophene-2-carboxamide analogues against extended-spectrum-β-lactamase producing clinical strain of Escherichia …

G Ahmad, A Khalid, MU Qamar, N Rasool, M Saadullah… - Molecules, 2023 - mdpi.com
Development in the fields of natural-product-derived and synthetic small molecules is in
stark contrast to the ongoing demand for novel antimicrobials to treat life-threatening …

Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study

MM Gad, A Abdelwaly, MA Helal - Journal of Biomolecular …, 2023 - Taylor & Francis
Activating mutations in the EGFR kinase domain are known to be a common cause of Non-
Small Cell Lung Cancer (NSCLC) and are thus targeted for treatment. First generation …

Targeting BRF2 in cancer using repurposed drugs

B Rashidieh, M Molakarimi, A Mohseni, SM Tria… - Cancers, 2021 - mdpi.com
Simple Summary BRF2, a subunit of the RNA polymerase III transcription complex, is
upregulated in a wide variety of cancers and is a potential therapeutic target; however, no …

Synthesis of Functionalized N-(4-Bromophenyl)furan-2-carboxamides via Suzuki-Miyaura Cross-Coupling: Anti-Bacterial Activities against Clinically Isolated Drug Resistant A. baumannii …

A Siddiqa, M Zubair, M Bilal, N Rasool, MU Qamar… - Pharmaceuticals, 2022 - mdpi.com
N-(4-bromophenyl) furan-2-carboxamide (3) was synthesized by the reaction furan-2-
carbonyl chloride (1) and 4-bromoaniline (2) in the presence of Et3N in excellent yields of …

Molecular docking and dynamics studies of cigarette smoke carcinogens interacting with acetylcholinesterase and butyrylcholinesterase enzymes of the central …

QMS Jamal, AH Alharbi - Environmental Science and Pollution Research, 2022 - Springer
The free radicals produced by cigarette smoking are responsible for tissue damage, heart
and lung diseases, and carcinogenesis. The effect of tobacco on the central nervous system …